Journal of the Neurological Sciences
Volume 222, Issue 1 , Pages 39-48 , 15 July 2004

Comfort care in severely disabled multiple sclerosis patients

  • Marc Rousseaux

      Affiliations

    • Corresponding Author InformationCorresponding author. Service de Rééducation Neurologique, Hôpital Swynghedauw, Centre Hospitalier Universitaire, 59037 Lille cedex, France. Tel.: +33-320444872; fax: +33-320445832.
    • ,
  • Dominic Pérennou

Received 28 August 2003 ,Revised 2 April 2004 ,Accepted 5 April 2004.

References 

  1. McDonnell GV, Hawkins SA. An assessment of the spectrum of disability and handicap in multiple sclerosis: a population-based study. Mult. Scler. 2001;7:111–117
  2. Rodriguez M, Siva A, Ward J, Stolps-Smith K, O'Brien P, Kurland L. Impairment, disability and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. Neurology. 1994;44:28–33
  3. Aronson KJ. Quality of life among persons with MS and their caregivers. Neurology. 1997;48:74–80
  4. Hughes JC, Enderby PM, Langton-Hewer R. Dysphagia and multiple sclerosis: a study and discussion of its nature and impact. Clin. Rehabil. 1994;8:18–26
  5. Hinds JP, Eidelman BH, Wald A. Prevalence of bowel dysfunction in multiple sclerosis: a population survey. Gastroenterology. 1990;98:1538–1542
  6. Betts CD, D'Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 1993;56:245–250
  7. Giannantoni A, Scivoletto G, Di Stasi SM, Agrò EF, Collura G, Vespasiani G. Lower urinary tract dysfunction and disability status in patients with multiple sclerosis. Arch. Phys. Med. Rehabil. 1999;80:437–441
  8. DasGupta R, Fowler CJ. Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies. Curr. Opin. Neurol. 2002;15:271–278
  9. Ganty G. Respiratory dysfunction in multiple sclerosis. Evaluation and treatment. MS Manag. 1999;6:10–16
  10. Ferini-Strambi L, Filippi M, Martinelli V, Rovaris M, Zucconi M, Comi G, et al.  Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain magnetic resonance imaging findings. J. Neurol. Sci. 1994;125:194–197
  11. Foley FW, Sanders A. Sexuality, multiple sclerosis and men. MS Manag. 1997;4:1–14
  12. Foley FW, Sanders A. Sexuality, multiple sclerosis and women. MS Manag. 1997;4:1–7
  13. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys. Ther. 1987;67:206–207
  14. Clanet MG, Brassat D. The management of multiple sclerosis patients. Curr. Opin. Neurol. 2000;13:263–270
  15. Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology. 1988;12:1830–1834
  16. Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol. Scand. 1991;84:197–200
  17. Chatel M, Lantéri-Minet M, Lebrun-Frenay C. Les douleurs dans la sclérose en plaques. Rev. Neurol. (Paris). 2001;157:1072–1078
  18. Vaney C. Understanding pain mechanisms in multiple sclerosis. MS Manag. 1996;3:11–18
  19. Shapiro RT. Symptom management in multiple sclerosis. Ann. Neurol. 1994;36:S123–S129
  20. Shapiro RT, Langer SL. Symptomatic therapy of multiple sclerosis. Curr. Opin. Neurol. 1994;7:229–233
  21. Krupp LB. Mechanisms, measurement, and management of fatigue in multiple sclerosis. In:  Thompson AJ,  Polman CH,  Hohlfeld R editor. Multiple sclerosis: clinical challenges and controversies. London: Martin Dunitz; 1997;p. 283–294
  22. Thompson AJ. Symptomatic treatment in multiple sclerosis. Curr. Opin. Neurol. 1998;11:305–309
  23. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction. Neurology. 1991;41:692–696
  24. Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, et al.  Depression and multiple sclerosis. Neurology. 1996;46:628–632
  25. Thompson AJ. Multiple sclerosis: rehabilitation measures. Semin. Neurol. 1998;18:397–403
  26. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33:1444–1452
  27. Sipe JC, Knobler RL, Braheny SN, Rice GPA, Panitch HS, Oldstone NBA. A neurologic rating scale (NRS) for multiple sclerosis. Neurology. 1984;34:1368–1372
  28. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, et al.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122:871–882
  29. Sharrack B, Hughes RA. Clinical scales for multiple sclerosis. J. Neurol. Sci. 1996;135:1–9
  30. Mahoney FI, Barthel DW. Functional evaluation: Barthel Index. Md. State Med. J. 1965;14:61–65
  31. Granger CV, Hamilton BB. The functional independence measure. In:  McDowell I,  Newell C editor. Measuring Health: A Guide to Rating Scales and Questionnaires. 2nd ed.. New York: Oxford University Press; 1987;p. 115–121
  32. Ware JE, Sherbourne CD. The MOOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med. Care. 1992;30:473–483
  33. Vickrey BG, Haxs RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual. Life Res. 1995;4:187–206
  34. Vernay D, Gerbaud L, Biolay S, Coste J, Debourse J, Aufauvre D, et al.  Qualité de vie et sclérose en plaques: validation de la version francophone d'un auto-questionnaire, le SEP-59. Rev. Neurol. (Paris). 2000;156:247–263
  35. Lahman H, Lankhorst GJ. Subjective weighting of disability: an approach to quality of life assessment in rehabilitation. Disabil. Rehabil. 1994;16:198–204
  36. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J. Neurol. Neurosurg. Psychiatry. 2000;69:217–221
  37. Hesse S, Reiter F, Konrad M, Jahnke MT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke. A randomized, double-blind, placebo-controlled trial. Clin. Rehabil. 1998;12:381–388
  38. Snow BJ, Tsui JKC, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double blind study. Ann. Neurol. 1990;28:512–515
  39. Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, et al.  Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J. Neurol. Neurosurg. Psychiatry. 2000;68:689–690
  40. Teasell RW. Managing advanced multiple sclerosis. Can Fam Physician 1993;39:1127–30, 1133–4, 1137–41.
  41. Palmisano L, Thompson A, Miller D, Whetten-Goldstein K, Battaglia MA, Patti F, et al.  Toward the standardisation of a home-based care delivery system in multiple sclerosis: report of a round table held in Bari, Italy, on April 10th, 1999. MS Manag. 2000;7:26–36
  42. Gulick EE. Social support among persons with multiple sclerosis. Res. Nurs. Health. 1994;17:195–206
  43. O'Brien MT. Multiple sclerosis: the role of social support and disability. Clin. Nurs. Res. 1993;2:67–85
  44. Pozzilli C, Brunetti M, Amicosante AM, Gasperini C, Ristori G, Palmisano L, et al.  Home based management in multiple sclerosis: results of a randomised controlled trial. J. Neurol. Neurosurg. Psychiatry. 2002;73:250–255
  45. Thompson AJ. Multiple sclerosis: symptomatic treatment. J. Neurol. 1996;243:559–565
  46. Rossiter DA, Edmundson A, Al Shahi R, Thompson AJ. Integrated care pathways in MS rehabilitation: completing the audit cycle. Mult. Scler. 1998;4:85–89
  47. Lotterie JA. Indications thérapeutiques à visée symptomatique: fatigue, douleurs, mouvements anormaux et rééducation. Rev. Neurol. (Paris). 2001;157:1091–1119
  48. Thompson AJ. Symptomatic management and rehabilitation in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2001;71(Suppl. II):ii22–ii27
  49. Brar SP, Smith MB, Nelson LM, Franklin GM, Gobble ND. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch. Phys. Med. Rehabil. 1991;72:186–189
  50. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev. 2001;4: (CD001332)
  51. Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, et al.  Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002;58:1404–1407
  52. Viel EJ, Perennou D, Ripart J, Pelissier J, Eledjam JJ. Neurolytic blockade of the obturator nerve for intractable spasticity of adductor thigh muscles. Eur. J. Pain. 2002;6:97–104
  53. Konstanzer A, Ceballos-Baumann AO, Dressnandt J, Conrad B. Lokale Injektionsbehandlung mit Botulinum-Toxin A bei schwerer Arm-und Beinspastik. Nervenarzt. 1993;64:517–523
  54. Grazko MA, Polo K, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology. 1995;45:712–717
  55. Penn RD. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J. Neurosurg. 1992;77:236–240
  56. Ochs G, Struppler A, Meyerson BA, Linderoth B, Gybels J, Gardner BP, et al.  Intrathecal baclofen for long term treatment of spasticity: a multi-center study. J. Neurol. Neurosurg. Psychiatry. 1989;52:933–939
  57. Coffey RJ, Cahill D, Steers W, Park TS, Ordia J, Meythaler J, et al.  Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J. Neurosurg. 1993;78:226–232
  58. Becker WJ, Harris CJ, Long ML, Ablett DP, Klein GM, DeForge DA. Long-term intrathecal baclofen therapy in patients with intractable spasticity. Can. J. Neurol. Sci. 1995;22:208–217
  59. Azouvi P, Mane M, Thiebaut JB, Denys P, Remy-Neris O, Bussel B. Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up. Arch. Phys. Med. Rehabil. 1996;77:35–39
  60. Clifford DB, Trotter JL. Pain in multiple sclerosis. Arch. Neurol. 1984;41:1270–1272
  61. Hooge JP, Redekop WK. Trigeminal neuralgia in multiple sclerosis. Neurology. 1995;45:1294–1296
  62. Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology. 1998;51:611–614
  63. DMKG Study Group . Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J. Neurol. 2003;250:542–545
  64. Johnson M, Ashton CH, Thomson JW. An in-depth study of long term users of transcutaneous electrical nerve stimulation (TENS). Implications for clinical use of TENS. Pain. 1991;44:221–229
  65. Ramsaransing G, Zwanikken C, De Keyser J. Worsening of symptoms of multiple sclerosis associated with carbamazepine. BMJ. 2000;320:1113
  66. Wissel J, Muller J, Dressnandt J, Heinen F, Naumann M, Topka H, et al.  Management of spasticity associated pain with botulinum toxin A. J. Pain Symptom Manage. 2000;20:44–49
  67. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 2003;17:21–29
  68. Krames E. Implantable devices for pain control: spinal cord stimulation and intrathecal therapies. Best Pract. Res., Clin. Anaesthesiol. 2002;16:619–649
  69. Sechi GP, Zuddas M, Piredda M, Agnetti V, Sau G, Piras ML, et al.  Treatment of cerebellar tremors with carbamazepine: a controlled trial with long-term follow-up. Neurology. 1989;39:1113–1115
  70. Trouillas P, Garde A, Robert JM, Renaud B, Adeleine P, Bard J, et al.  Régression du syndrome cérébelleux sous administration à long terme de 5-HTP ou de l'association 5-HTP bensérazide: 26 observations quantifiées et traitées par ordinateur. Rev. Neurol. (Paris). 1982;138:415–435
  71. Trouillas P, Xie J, Getenet JC, Adeleine P, Nighoghossian N, Honnorat J, et al.  Effet de la buspirone, un agoniste sérotoninergique 5-HT-1A sur l'ataxie cérébelleuse: une étude pilote. Rev. Neurol. (Paris). 1995;151:708–713
  72. Rice GP, Lesaux J, Vandervoort P, MacEwan L, Ebers GC. Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J. Neurol. Neurosurg. Psychiatry. 1997;62:282–284
  73. Nguyen JP, Feve A, Cesaro P, Keravel Y. Long-term follow-up of patients with multiple sclerosis and action tremor treated by thalamic stimulation. Mov. Disord. 1998;13(Suppl. 2):132
  74. Montgomery EB, Baker KB, Kinkel PR, Barnett G. Chronic thalamic stimulation for the tremor of MS. Neurology. 1999;53:625–628
  75. Wiles CM, Newcombe RG, Fuller KJ, Shaw S, Furnival-Doran J, Pickersgill TP, et al.  Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2001;70:174–179
  76. Di Fabio RP, Soderberg J, Choi T, Hansen CR, Schapiro RT. Extended outpatient rehabilitation: its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis. Arch. Phys. Med. Rehabil. 1998;79:141–146
  77. Krupp LB, Coyle PK, Doscher C, Miller AE, Cross AH, Jandorf L, et al.  Fatigue therapy in multiple sclerosis: results of a double-blind, randomised, parallel trial of amantadine, pemoline and placebo. Neurology. 1995;45:1956–1961
  78. Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann. Neurol. 1990;27:186–192
  79. Bever CT, Leslie J, Camenga DL, Panitch HS, Johnson KP. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Ann. Neurol. 1990;27:421–427
  80. Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GP. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology. 1992;42:1468–1471
  81. Kozlowski O, Mazzoli B, Henguelle C, Rousseaux M. Prise en charge des troubles de déglutition d'origine neurologique. Cah. Nutr. 2002;37:199–205
  82. Fowler CJ, Beck RO, Gerrard S, Betts CD, Fowler CG. Intravesical capsaicin for treatment of detrusor hyperreflexia. J. Neurol. Neurosurg. Psychiatry. 1994;57:169–173
  83. Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N. Engl. J. Med. 2000;342:665
  84. Gallien P, Robineau S, Verin M, Le Bot MP, Nicolas B, Brissot R. Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch. Phys. Med. Rehabil. 1998;79:715–717
  85. Kinn AC, Larsson PO. Desmopressin: a new principle for symptomatic treatment of urgency and incontinence in patients with multiple sclerosis. Scand. J. Urol. Nephrol. 1990;24:109–112
  86. Valiquette G, Herbert J, Meade D. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch. Neurol. 1996;53:1270–1275
  87. Leigh RJ, Averbuch-Heler L, Tomsak RL, Remier BF, Yaniglos SS, Dell'Osso LF. Treatment of abnormal eye movements that impair vision: strategies based on current concept of physiology and pharmacology. Ann. Neurol. 1994;36:129–141
  88. Averbuch-Heller L, Tusa RJ, Fuhry L, Rottach KG, Ganser GL, Heide W, et al.  A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann. Neurol. 1997;41:818–825
  89. Averbuch-Heller L. Acquired nystagmus. Curr. Treat. Options Neurol. 1999;1:68–73
  90. Lee J, Elston J, Vickers S, Powell C, Ketley J, Hogg C. Botulinum toxin therapy for squint. Eye. 1988;2:24–28
  91. Olgiati R, Girr A, Hugi L, Haegi V. Respiratory muscle training in multiple sclerosis: a pilot study. Schweiz. Arch. Neurol. Psychiatr. 1989;140:46–50
  92. Smeltzer SC, Lavietes MH, Cook SD. Expiratory training in multiple sclerosis. Arch. Phys. Med. Rehabil. 1996;77:909–912
  93. Greene YM, Tariot PN, Wishart H, Cox C, Holt CJ, Schwid S, et al.  A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J. Clin. Psychopharmacol. 2000;20:350–356

PII: S0022-510X(04)00102-9

doi: 10.1016/j.jns.2004.04.002

Journal of the Neurological Sciences
Volume 222, Issue 1 , Pages 39-48 , 15 July 2004

Article Tools